AbbVie Inc. Announced Q1 2026 Earnings on April 29, 2026, Reporting "Total net revenues were $15 billion beating our expectations by $300 million and reflecting robust sales growth of 12.4%."

AbbVie Inc. reported first quarter 2026 results with total net revenues for the quarter of $15 billion, reflecting robust sales growth of 12.4%.

For the first quarter, the company achieved adjusted earnings per share of $2.65.

Adjusted gross margin for the quarter was 83.6% of sales, adjusted R&D expense was 15.1% of sales, and adjusted SG&A expense was 22.7% of sales.

Management noted the adjusted operating margin ratio was 40.8% of sales for the first quarter.

Management noted momentum in immunology and neuroscience, which are both delivering share gains in growing markets.

The company announced the U.S. regulatory submissions of Rinvoq for Alopecia Areata and Skyrizi subcutaneous induction in Crohn's disease.

AbbVie expanded its emerging oncology pipeline by closing the Remagen agreement, giving the company a novel PD-1 VEGF bispecific antibody. In obesity, positive top line results were announced for the long-acting amylin analog ABBV-295, demonstrating weight loss of nearly 10% after 12 weeks of treatment.

Management also announced a $1.4 billion investment to build a pharmaceutical manufacturing campus in North Carolina and a $380 million investment for 2 new plants in North Chicago.

For the full year 2026, AbbVie raised its adjusted earnings per share guidance to between $14.08 and $14.28.

The company now expects full year total net revenues of approximately $67.3 billion.

For the second quarter of 2026, management anticipates net revenues of approximately $16.7 billion and adjusted earnings per share between $3.74 and $3.78.

The company is forecasting a second quarter adjusted operating margin ratio of approximately 50%.